Novartis Agrees To $6.8 Billion Medicines Co. Deal

Novartis Agrees to $6.8 Billion Medicines Co. Deal

Bloomberg Television

Novartis acquires The Medicines Company for $9.7 billion

CNBC Television

Novartis as a focused innovative medicines company

Novartis not joining the 'frenzy' of weight loss drugs, CEO says

CNBC International News

The Medicines Company's Alex Denner on Novartis deal to buy the company

CNBC Television

Focus remains on R&D to drive growth of blockbuster drugs, says Novartis CEO

CNBC International News

Novartis generated $40 billion in innovative medicine sales, says CEO

CNBC Television

Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm

CNBC International News

Strategy to become the most valued and trusted medicines company

Novartis CEO: We expect our six key drugs to grow ahead of analyst expectations

CNBC Television

Novartis CEO: Our leukemia drug Scemblix is a potential $3 billion plus medicine

CNBC Television

Novartis agrees $9.7bn deal for US heart drug maker

Boyd Digital: Business News

Novartis CEO Vas Narasimhan: Our medicines are starting to take market share and deliver on promises

CNBC Television

Novartis CEO: Spinoffs will see us succeed as a pure-play innovative medicines company

CNBC International News

Swiss pharma giant Novartis expects China to be its second biggest market by 2024

China International Import Expo

Novartis CEO on the impact of the U.S. election for pharma

CNBC International News

How we are bringing medicines to millions of patients around the world

Novartis Careers

Novartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin off

CNBC International News

Novartis AG CEO Talks Medicinal Sales | Bloomberg Talks

Bloomberg Podcasts

Ep. 268 - Biosecure Setback & Novartis' $1B PTC Deal

BioCentury Video